by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
MPNs and Dementia Risk: New Study Finds Link Between Myeloproliferative Neoplasms and Cognitive Decline
by David Wallace A new study published in the European Journal of Haematology has uncovered a significant association between blood cancers known as myeloproliferative neoplasms (MPNs) and an increased risk of dementia. This Danish population-based cohort study, spanning over two decades, provides valuable insights into the long-term neurological impacts of chronic blood cancers and inflammation […]
The Unseen Journey: Bringing MPNs to Life with Generative AI
Sponsored Post Like countless busy parents juggling family responsibilities, when Ben began experiencing unexplained symptoms – such as headaches, fatigue and brain fog – he initially pushed them aside. Clarity only came when a physical exam for a new job uncovered something was wrong. Ben’s tests revealed he had an unexpectedly high platelet count. A […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
